Rabbit Anti-LYPD3 Recombinant Antibody (CBYCL-593) (CBMAB-L0494-YC)

See all LYPD3 antibodies

Online Inquiry

Summary

Host Animal

Rabbit

Specificity

Human

Clone

CBYCL-593

Antibody Isotype

IgG

Application

ELISA, IF, WB

Basic Information

Immunogen

Recombinant Human C4.4A / LYPD3 protein

Specificity

Human

Antibody Isotype

IgG

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage

Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Epitope

aa 1-286

Target

Full Name

LY6/PLAUR domain containing 3

Introduction

LYPD3 supports cell migration. LYPD3 may be involved in urothelial cell-matrix interactions and tumor progression.

Entrez Gene ID

27076

UniProt ID

O95274

Alternative Names

C4.4A

Function

Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.

Biological Process

Cell-matrix adhesionIEA:Ensembl
Negative regulation of smooth muscle cell apoptotic processManual Assertion Based On ExperimentIGI:ARUK-UCL

Cellular Location

Cell membrane

PTM

N-glycosylated and O-glycosylated.

More Infomation

References

Hu, Y. D., Wu, K., Liu, Y. J., Zhang, Q., Shen, H., Ji, J., ... & Xi, S. Y. (2023). LY6/PLAUR domain containing 3 (LYPD3) maintains melanoma cell stemness and mediates an immunosuppressive microenvironment. Biology Direct, 18(1), 72.

Hu, T., Zhang, Y., Yang, T., He, Q., & Zhao, M. (2022). LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia. Frontiers in Genetics, 13, 795820.

Kehler, P., Neumann, T., Jaekel, A., Gellert, J., Danielczyk, A., Weiß, L., ... & Weiske, M. (2022). 1347 Targeting of a cancer-associated LYPD3 glycoform for tumor therapy.

Hu, P., Huang, Y., Gao, Y., Yan, H., Li, X., Zhang, J., ... & Zhao, Y. (2020). Elevated expression of LYPD3 is associated with lung adenocarcinoma carcinogenesis and poor prognosis. DNA and Cell Biology, 39(4), 522-532.

Yue, J., Zhu, T., Yang, J., Si, Y., Xu, X., Fang, Y., & Fu, W. (2020). CircCBFB-mediated miR-28-5p facilitates abdominal aortic aneurysm via LYPD3 and GRIA4. Life sciences, 253, 117533.

Gruet, M., Cotton, D., Coveney, C., Boocock, D. J., Wagner, S., Komorowski, L., ... & Powe, D. G. (2020). β2-adrenergic signalling promotes cell migration by upregulating expression of the metastasis-associated molecule LYPD3. Biology, 9(2), 39.

Q & As

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Review & reward

Have you used Rabbit Anti-LYPD3 Recombinant Antibody (CBYCL-593)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Protocols

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Associated Products

Related Products

Mouse Anti-LYPD3 Recombinant Antibody (CBYJL-2242)

Recombinant Mouse Anti-LYPD3 Recombinant Antibody (11F1)

Mouse Anti-LYPD3 Recombinant Antibody (3G10)

Mouse Anti-LYPD3 Recombinant Antibody (A966)

Mouse Anti-LYPD3 Recombinant Antibody (CBYJL-2243)

Rabbit Anti-LYPD3 Recombinant Antibody (SP204)

Rabbit Anti-LYPD3 Recombinant Antibody (CBYCL-592)

Rabbit Anti-LYPD3 Recombinant Antibody (CBFYC-0066)

Rabbit Anti-LYPD3 Recombinant Antibody (CBFYC-2933)

Rabbit Anti-LYPD3 Recombinant Antibody (SP250)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more